We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 20.50 | 18.00 | 23.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
TIDMSUMM
Summit Therapeutics plc
('Summit' or the 'Company')
Exercise of Restricted Stock Units, Director Dealings and Total Voting
Rights
Oxford, UK, and Cambridge, MA, US, 24 October 2018 -- Summit
Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces the exercise by the
following Non-Executive Directors of restricted stock units ('RSUs')
that entitled the holder to subscribe for an ordinary share of one penny
nominal value at a subscription price of one penny per ordinary share.
The RSUs were granted under the Company's 2017 Remuneration Policy and
were eligible for exercise for a limited time after completion of a
vesting period of one year. Details of the exercise of the RSUs, all of
which took place on 24 October 2018, and which have been duly notified
to the Company, are summarised below.
Director Position RSU's Exercised
-------------------- -------------- ---------------
Non-Executive
Frank Armstrong Chairman 41,666
-------------------- -------------- ---------------
Non-Executive
Leopoldo Zambeletti Director 19,444
-------------------- -------------- ---------------
Non-Executive
Valerie Andrews Director 19,444
-------------------- -------------- ---------------
Non-Executive
Dave Wurzer Director 19,444
-------------------- -------------- ---------------
Total 99,998
------------------------------------ ---------------
Summit has also been notified that Leopoldo Zambeletti has sold 11,358
ordinary shares, at a price of 28.1 pence per ordinary share to cover
the tax and other charges associated with the exercise of the RSUs.
Following the exercise of the RSUs, the shareholdings of the
Non-Executive Directors are as follows:
Shareholding
(ordinary % of Issued
Director Position shares) Share Capital
-------------------- -------------- ------------ ----------------
Non-Executive
Frank Armstrong Chairman 122,204* 0.15%
-------------------- -------------- ------------ ---
Non-Executive
Leopoldo Zambeletti Director 15,979 0.02%
-------------------- -------------- ------------ ---
Non-Executive
Valerie Andrews Director 49,123 0.06%
-------------------- -------------- ------------ ---
Non-Executive
Dave Wurzer Director 46,123 0.06%
-------------------- -------------- ------------ ---
Total 233,429 0.29%
------------------------------------ ------------ ---
* Includes shares held by persons closely associated with the director
The Company also announces the exercise of a further 38,888 RSUs by
former Non-Executive Directors of Summit.
Application has been made to the London Stock Exchange for the admission
of 138,886 ordinary shares to trading on AIM and it is expected that
admission will become effective and that dealings will commence at 8.00
a.m. on 30 October 2018.
Total Voting Rights
Following the exercise of these RSUs, the total number of ordinary
shares following admission will be 82,264,881 with each ordinary share
carrying the right to one vote. The Company has no shares in Treasury;
therefore following admission the total number of voting rights in
Summit will be 82,264,881. This figure may be used by shareholders as
the denominator for the calculations by which they will determine if
they are required to notify an interest in, or change to their interest
in, the share capital of the Company under the FCA's Disclosure and
Transparency Rules.
This announcement contains inside information for the purposes of
Article 7 of EU Regulation 596/2014 (MAR).
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new
mechanism antibiotics are designed to become the new standards of care
for the benefit of patients, and create value for payors and healthcare
providers. We are currently developing new mechanism antibiotics for C.
difficile infection and gonorrhoea and are using our proprietary Discuva
Platform to expand our pipeline. For more information, visit
www.summitplc.com and follow us on Twitter @summitplc.
Contacts
Summit
Glyn Edwards / Richard Pye (UK
office) Tel: 44 (0)1235 443 951
Erik Ostrowski / Michelle Avery
(US office) +1 617 225 4455
Cairn Financial Advisers LLP
(Nominated Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
Notification of Transactions pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the persons discharging managerial
responsibilities/person closely associated
-----------------------------------------------------------------
a) Name
1. Frank Armstrong
2. Leopoldo Zambeletti
3. Valerie Andrews
4. Dave Wurzer
-------------------------- -------------------------------------
2 Reason for the notification
-----------------------------------------------------------------
a) Position / status
1. Non-Executive Chairman
2. Non-Executive Director
3. Non-Executive Director
4. Non-Executive Director
-------------------------- -------------------------------------
b) Initial notification Initial notification
/ Amendment
-------------------------- -------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
-----------------------------------------------------------------
a) Name Summit Therapeutics plc
-------------------------- -------------------------------------
b) LEI 213800NRW8AOMYMTBD89
-------------------------- -------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
-----------------------------------------------------------------
Description of the Ordinary shares of 1 penny each
financial instrument,
type of instrument
a) Identification code GB00BN40HZ01
-------------------------- -------------------------------------
b) Nature of the transactions Exercise of restricted stock
units (RSUs) to subscribe for
ordinary shares of one penny
nominal value
-------------------------- -------------------------------------
Price(s) Volume(s)
-------------------------- ------------------ -------------
(i)-(iv) 1p
(exercise price) 1. 41,666
(ii)-(iv)
19,444
------------------ -------------
c) Price(s) and volume(s)
-------------------------- -------------------------------------
d) Aggregated information
- Aggregated volume 99,998 ordinary shares
- Price 1 penny (exercise price)
-------------------------- -------------------------------------
e) Date of the transactions 24 October 2018
-------------------------- -------------------------------------
f) Place of the transactions Outside a trading venue
-------------------------- -------------------------------------
1 Details of the persons discharging managerial
responsibilities/person closely associated
-------------------------------------------------------------------
a) Name 1. Leopoldo Zambeletti
---- -------------------------- -------------------------------------
2 Reason for the notification
---- -----------------------------------------------------------------
a) Position / status 1. Non-Executive Director
---- -------------------------- -------------------------------------
b) Initial notification Initial notification
/ Amendment
---- -------------------------- -------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
---- -----------------------------------------------------------------
a) Name Summit Therapeutics plc
---- -------------------------- -------------------------------------
b) LEI 213800NRW8AOMYMTBD89
---- -------------------------- -------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
---- -----------------------------------------------------------------
Description of the Ordinary shares of 1 penny each
financial instrument,
type of instrument
a) Identification code GB00BN40HZ01
---- -------------------------- -------------------------------------
b) Nature of the transactions Sale of ordinary shares of one
penny nominal value
---- -------------------------- -------------------------------------
Price(s) Volume(s)
-------------------------- ------------------ -------------
1. 28.1 pence 1. 11,358
------------------ -------------
c) Price(s) and volume(s)
---- -------------------------- -------------------------------------
d) Aggregated information
- Aggregated volume 11,358 ordinary shares
- Average Price 28.1 pence
---- -------------------------- -------------------------------------
e) Date of the transactions 24 October 2018
---- -------------------------- -------------------------------------
f) Place of the transactions London Stock Exchange
---- -------------------------- -------------------------------------
-END-
(END) Dow Jones Newswires
October 24, 2018 11:15 ET (15:15 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Summit Therapeutics Chart |
1 Month Summit Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
